Tempest Therapeutics (TPST) Competitors $0.91 -0.04 (-4.02%) (As of 12:03 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TPST vs. SAVA, SGMT, OGI, ATOS, PBYI, GOSS, ACTU, FTLF, CHRS, and MCRBShould you be buying Tempest Therapeutics stock or one of its competitors? The main competitors of Tempest Therapeutics include Cassava Sciences (SAVA), Sagimet Biosciences (SGMT), Organigram (OGI), Atossa Therapeutics (ATOS), Puma Biotechnology (PBYI), Gossamer Bio (GOSS), Actuate Therapeutics (ACTU), FitLife Brands (FTLF), Coherus BioSciences (CHRS), and Seres Therapeutics (MCRB). These companies are all part of the "pharmaceutical products" industry. Tempest Therapeutics vs. Cassava Sciences Sagimet Biosciences Organigram Atossa Therapeutics Puma Biotechnology Gossamer Bio Actuate Therapeutics FitLife Brands Coherus BioSciences Seres Therapeutics Cassava Sciences (NASDAQ:SAVA) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, community ranking, dividends, valuation and analyst recommendations. Do insiders and institutionals hold more shares of SAVA or TPST? 38.1% of Cassava Sciences shares are owned by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are owned by institutional investors. 12.2% of Cassava Sciences shares are owned by company insiders. Comparatively, 4.7% of Tempest Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is SAVA or TPST more profitable? Cassava Sciences' return on equity of -88.05% beat Tempest Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cassava SciencesN/A -88.05% -64.98% Tempest Therapeutics N/A -187.44%-82.61% Which has higher earnings and valuation, SAVA or TPST? Cassava Sciences is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCassava SciencesN/AN/A-$97.22M-$1.38-2.49Tempest TherapeuticsN/AN/A-$29.49M-$1.53-0.60 Does the MarketBeat Community favor SAVA or TPST? Tempest Therapeutics received 2 more outperform votes than Cassava Sciences when rated by MarketBeat users. Likewise, 65.79% of users gave Tempest Therapeutics an outperform vote while only 65.33% of users gave Cassava Sciences an outperform vote. CompanyUnderperformOutperformCassava SciencesOutperform Votes9865.33% Underperform Votes5234.67% Tempest TherapeuticsOutperform Votes10065.79% Underperform Votes5234.21% Do analysts rate SAVA or TPST? Cassava Sciences presently has a consensus price target of $111.50, suggesting a potential upside of 3,150.73%. Tempest Therapeutics has a consensus price target of $20.00, suggesting a potential upside of 2,090.34%. Given Cassava Sciences' higher probable upside, equities analysts plainly believe Cassava Sciences is more favorable than Tempest Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cassava Sciences 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Tempest Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, SAVA or TPST? Cassava Sciences has a beta of -0.85, suggesting that its share price is 185% less volatile than the S&P 500. Comparatively, Tempest Therapeutics has a beta of -1.78, suggesting that its share price is 278% less volatile than the S&P 500. Does the media prefer SAVA or TPST? In the previous week, Cassava Sciences had 10 more articles in the media than Tempest Therapeutics. MarketBeat recorded 13 mentions for Cassava Sciences and 3 mentions for Tempest Therapeutics. Tempest Therapeutics' average media sentiment score of 0.72 beat Cassava Sciences' score of -0.19 indicating that Tempest Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cassava Sciences 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Tempest Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryCassava Sciences beats Tempest Therapeutics on 8 of the 15 factors compared between the two stocks. Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Tempest Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TPST and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TPST vs. The Competition Export to ExcelMetricTempest TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$39.85M$6.73B$5.20B$8.97BDividend YieldN/A7.94%5.23%4.04%P/E Ratio-0.604.7285.7113.39Price / SalesN/A352.931,469.4286.49Price / CashN/A22.8835.2935.09Price / Book0.665.604.914.96Net Income-$29.49M$151.32M$117.36M$224.10M7 Day Performance-2.90%3.14%2.75%2.01%1 Month Performance0.41%-1.67%1.71%9.79%1 Year Performance-73.38%31.88%36.01%29.97% Tempest Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TPSTTempest Therapeutics3.0432 of 5 stars$0.91-4.0%$20.00+2,090.3%-72.3%$39.85MN/A-0.6020Short Interest ↓Gap UpSAVACassava Sciences3.823 of 5 stars$3.50-8.9%$111.50+3,085.7%-76.8%$168.39MN/A-2.5430High Trading VolumeSGMTSagimet Biosciences2.1599 of 5 stars$5.48-3.7%$21.60+294.2%+41.4%$168.07M$2M0.008OGIOrganigram0.6631 of 5 stars$1.51+0.2%N/A+13.4%$164.83M$120.01M-3.60860Positive NewsATOSAtossa Therapeutics1.6074 of 5 stars$1.28-1.5%$6.75+427.3%+67.1%$161.02MN/A-5.918Positive NewsPBYIPuma Biotechnology4.2291 of 5 stars$3.28-3.2%$7.00+113.4%-14.7%$161.02M$235.60M7.06185Gap DownGOSSGossamer Bio4.1498 of 5 stars$0.70+0.5%$9.20+1,211.8%-13.7%$158.92M$105.32M-2.18180Positive NewsACTUActuate TherapeuticsN/A$8.12-0.1%N/AN/A$158.60MN/A0.0010FTLFFitLife Brands3.4139 of 5 stars$33.34-1.2%$40.00+20.0%+68.4%$153.30M$62.76M19.9620Short Interest ↑CHRSCoherus BioSciences3.7949 of 5 stars$1.33+8.6%$6.13+362.3%-40.4%$152.65M$257.24M-16.07246Options VolumeNews CoverageGap UpMCRBSeres Therapeutics3.8896 of 5 stars$0.89-9.1%$5.08+470.4%-13.4%$152.16M$126.32M-4.26233 Related Companies and Tools Related Companies SAVA Alternatives SGMT Alternatives OGI Alternatives ATOS Alternatives PBYI Alternatives GOSS Alternatives ACTU Alternatives FTLF Alternatives CHRS Alternatives MCRB Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TPST) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tempest Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tempest Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TPST Stock Alerts